NCT06773195: A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 37 planned
- Started
- 7 Jan 2025
- Primary completion
- Jan 2028
- Arms
- JAK/MEK inhibition with Ruxolitinib and Ulixertinib
- Results
- None posted
- 7 Jan 2025: Trial started
- 14 Jan 2025: Trial registered